You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

LATANOPROST Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Latanoprost

A generic version of LATANOPROST was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LATANOPROST?
  • What are the global sales for LATANOPROST?
  • What is Average Wholesale Price for LATANOPROST?
Drug patent expirations by year for LATANOPROST
Drug Prices for LATANOPROST

See drug prices for LATANOPROST

Drug Sales Revenue Trends for LATANOPROST

See drug sales revenues for LATANOPROST

Recent Clinical Trials for LATANOPROST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aneira Pharma, Inc.Phase 1
DataPharm Australia, CMAX Clinical Research, Agilex AustraliaPhase 1
Peregrine OphthalmicPhase 1

See all LATANOPROST clinical trials

Pharmacology for LATANOPROST
Anatomical Therapeutic Chemical (ATC) Classes for LATANOPROST

US Patents and Regulatory Information for LATANOPROST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amring Pharms LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 200925-001 Mar 22, 2011 AT RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ryan Labs LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 202077-001 Feb 11, 2013 AT RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Epic Pharma Llc LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 090887-001 Jul 19, 2011 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

LATANOPROST Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Latanoprost

Introduction to Latanoprost

Latanoprost is a prostaglandin analogue used primarily to treat increased intraocular pressure associated with conditions such as glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor, thereby reducing intraocular pressure and preventing optic nerve damage and vision loss[3].

Global Market Size and Growth

The global latanoprost market was valued at USD 1.3 billion in 2023 and is projected to reach USD 1.6 billion by 2033, growing at a compound annual growth rate (CAGR) of 2.1% from 2024 to 2033. This growth is driven by the increasing prevalence of glaucoma and ocular hypertension, particularly among the aging population[3].

Regional Market Dynamics

North America

North America holds a significant share of the global latanoprost market, with a market size of USD 608.48 million in 2024. This region is expected to grow at a CAGR of 0.7% from 2024 to 2031. The brand drug segment dominates this market, benefiting from market exclusivity during the patent-protected period. However, the eventual expiration of patents will lead to the entry of generic alternatives, which may impact market dynamics[1].

Asia Pacific

The Asia Pacific region is the fastest-growing market for latanoprost, with a market size of USD 349.88 million in 2024 and a projected CAGR of 4.5% from 2024 to 2031. This growth is attributed to the large and diverse population, increasing prevalence of glaucoma and ocular hypertension, and improving access to healthcare services in countries like India and China[1][3].

Europe

Europe's latanoprost market was valued at a significant portion of the global revenue, although the exact figure for Europe is not specified in the sources. It is expected to grow at a CAGR of 1% from 2024 to 2031. The market here is driven by advanced healthcare infrastructure and a high prevalence of glaucoma and ocular hypertension[1].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa (MEA) also present growth opportunities, albeit at a slower pace. Latin America's market size was USD 76.06 million in 2024, with a CAGR of 1.9% from 2024 to 2031. The MEA region had a market size of USD 30.42 million in 2024, with a CAGR of 2.2% from 2024 to 2031. These regions require tailored marketing strategies and collaborations with local stakeholders to address unique cultural, economic, and regulatory landscapes[1].

Key Drivers of Market Growth

Increasing Prevalence of Glaucoma and Ocular Hypertension

The rise in the prevalence of glaucoma and ocular hypertension, especially among the aging population, is a significant driver of the latanoprost market. As the global population ages, the demand for effective treatments for these conditions increases[3].

Technological Advancements

Advancements in drug formulations, such as combination therapies and sustained-release formulations, enhance the effectiveness of latanoprost and improve patient compliance. These innovations are crucial for the market's growth[3].

Government Initiatives and Healthcare Infrastructure

Government initiatives aimed at improving access to healthcare and making medications more affordable contribute to the market's expansion. Expanding healthcare infrastructure, particularly in emerging markets, also boosts demand for latanoprost[3].

Financial Performance of Key Players

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical, a major player in the ophthalmic drugs market, has shown strong financial performance. In Q1 FY2023, Santen reported a revenue growth of 9.0% (excluding FX impact), driven by a strong start across all regions, including a market recovery in China. The company's core operating profit improved significantly due to strong sales and cost optimization efforts[2].

Market Challenges

Patent Expiration and Generic Competition

The eventual expiration of patents for brand-name latanoprost products will lead to the entry of generic alternatives, which can significantly impact market dynamics and pricing. Pharmaceutical companies need to adapt to these changes by developing new formulations or expanding their product portfolios[1].

Regional Variations and Regulatory Landscapes

The latanoprost market is influenced by diverse regional needs and regulatory landscapes. Companies must adopt nuanced strategies that consider these variations to succeed in different markets[1].

Industry Trends

Combination Therapies and Sustained-Release Formulations

The development of combination therapies and sustained-release formulations is a key trend in the latanoprost market. These innovations improve therapeutic outcomes and patient compliance, contributing to market growth[3].

Growing Demand in Emerging Markets

Emerging markets, particularly in the Asia-Pacific region, are experiencing a surge in demand for latanoprost due to better access to healthcare services and a growing burden of age-related eye diseases[3].

Key Takeaways

  • The global latanoprost market is projected to grow from USD 1.3 billion in 2023 to USD 1.6 billion by 2033.
  • North America and Asia Pacific are key regions driving market growth.
  • Technological advancements and government initiatives are significant drivers of the market.
  • Patent expiration and generic competition pose challenges for brand-name products.
  • Emerging markets offer substantial growth opportunities due to improving healthcare infrastructure and increasing prevalence of glaucoma and ocular hypertension.

FAQs

What is the current global market size of latanoprost?

The global latanoprost market was valued at USD 1.3 billion in 2023[3].

What is the projected growth rate of the latanoprost market from 2024 to 2033?

The latanoprost market is expected to grow at a CAGR of 2.1% from 2024 to 2033[3].

Which region is the fastest-growing market for latanoprost?

The Asia Pacific region is the fastest-growing market for latanoprost, with a projected CAGR of 4.5% from 2024 to 2031[1].

What are the main drivers of the latanoprost market?

The main drivers include the increasing prevalence of glaucoma and ocular hypertension, technological advancements in drug formulations, and government initiatives to improve healthcare access[3].

How does patent expiration impact the latanoprost market?

Patent expiration leads to the entry of generic alternatives, which can impact market dynamics and pricing for brand-name products[1].

Sources

  1. Cognitive Market Research: Latanoprost Market Report.
  2. Santen Pharmaceutical: Q1 FY2023 Financial Results.
  3. Allied Market Research: Latanoprost Market Size, Report | Industry Analysis, 2033.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.